Zealand Pharma — April 2023
-
har også ledt - Bava lå +3% længe ved ikke om det er "tilpasning" (biotek)
-
Godmorgen
-
God morgen
-
Mornings
-
Høj volumen i den første 1/2 time og vi er gået under 210. Der er tydeligvis nogen som fortsat gerne vil have kursen og det på trods af der faktisk er blevet reduceret short i det sidste stykke tid. Det ligger pres på at ZP må leverer på de ting som de har lovet.
-
….vil have kursen ned og …
-
Hvorfor tror du at der var så høj volumen i den første halve time? kursen gik på meget kort tid fra 219 til 208
-
Hvem har en interesse i lav kurs lige nu? Det er vel shorterne som gerne vil ud inden de store gode nyheder kommer. Derfor er vel algoritme handel (= høj volumen) så på opgaven med at holde lav kurs og mulighed for at genkøbe. Men dette er ren spekulation fra min side
-
Tak for dit svar. Det lyder meget fornuftigt
-
Bloomberg oplyser at Centerview Partners er valgt af ZP til at hjælpe med at finde en partner til CHI / dasiglucagon projekter.
-
-
Jeg er på vej hjem og på Schipol lufthavn lige nu men har nu fået læst lidt sf artiklen og jeg må dele lidt her:
-
Zealand Pharma is working with the investment bank to identify potential partners for a key rare disease treatment targeting short bowel syndrome, as well as for some dasiglucagon-based medications, the people said. The process may end up leading to a full sale of the company, which has previously been studied by large pharmaceutical firms, they said.
-
Og lidt senere “ Deliberations are at an early stage and there’s no certainty they will lead to a transaction, the people said, asking not to be identified as the matter is private. A representative for the company declined to comment beyond previous statements, while a spokesperson for Centerview didn’t immediately respond to a request for comment.”
-
Det bliver meget interessant hvordan den åbner i morgen.
-
Hmm…det var en interessant nyhed
HVIS jeg var short, så ville jeg se at få “ræven” ud Ellers KAN det blive dyrt -
"In March, Pfizer Inc. agreed to buy cancer-drug maker Seagen Inc. for $43 billion. Amgen Inc. struck a $27.8 billion deal in December for autoimmune disease drugmaker Horizon Therapeutics Plc in a bid to boost sales."
"Apellis Pharmaceuticals Inc., a biotech firm focused on rare diseases and ophthalmology, is drawing takeover interest from larger drugmakers, Bloomberg News reported in March"
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind